Detroit

Michigan

The Whitney

Tuesday, September 27, 2011

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other physicians in active clinical practice interested and/or involved in the management of patients with lung cancer.

Objectives

After successfully completion of this course, participants should be able to:

  • Select a therapeutic regimen based upon histology
  • Deduce the appropriate role of biologic, molecular and genetic markers that guide the therapeutic decision- making process
  • Evaluate the clinical utility of two novel agents for the management and treatment of patients with NSCLC

Scientific Agenda

5:30 pm

Registration

6:00 pm

Dinner served

6:30 pm

Welcome and audience survey via ARS

Each presentation will be followed by a clinical case discussion and a question and answer session

6:40 pm

Differentiating NSCLC therapy based on histology

7:15 pm

Practical implications of emerging biologic, molecular and genetic targets

7:50 pm

Overview of emerging agents in NSCLC: Antiangiogenic therapy, TKIs alone and in combination, immunotherapies, and others

8:25 pm

Closing remarks

8:30 pm

Adjournment

Registration

Registration is Full. If you show up onsite for this meeting we may not be able to accommodate you. You will be asked to wait until preregistered attendees are accommodated and then, if we have space available, you will be allowed to participate on a first come, first serve basis.

Cancellation: If you need to cancel your attendance, please notify our office in writing at meetings@imedex.com no later than Thursday, September 22, 2011

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

 

Imedex® is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society. © 2011 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.